Literature DB >> 10557356

Long-term expression of protein kinase C in adult mouse hearts improves postischemic recovery.

R Tian1, W Miao, M Spindler, M M Javadpour, R McKinney, J C Bowman, P M Buttrick, J S Ingwall.   

Abstract

Activation of protein kinase C (PKC) protects the heart from ischemic injury; however, its mechanism of action is unknown, in part because no model for chronic activation of PKC has been available. To test whether chronic, mild elevation of PKC activity in adult mouse hearts results in myocardial protection during ischemia or reperfusion, hearts isolated from transgenic mice expressing a low level of activated PKCbeta throughout adulthood (beta-Tx) were compared with control hearts before ischemia, during 12 or 28 min of no-flow ischemia, and during reperfusion. Left-ventricular-developed pressure in isolated isovolumic hearts, normalized to heart weight, was similar in the two groups at baseline. However, recovery of contractile function was markedly improved in beta-Tx hearts after either 12 (97 +/- 3% vs. 69 +/- 4%) or 28 min of ischemia (76 +/- 8% vs. 48 +/- 3%). Chelerythrine, a PKC inhibitor, abolished the difference between the two groups, indicating that the beneficial effect was PKC-mediated. (31)P NMR spectroscopy was used to test whether modification of intracellular pH and/or preservation of high-energy phosphate levels during ischemia contributed to the cardioprotection in beta-Tx hearts. No difference in intracellular pH or high-energy phosphate levels was found between the beta-Tx and control hearts at baseline or during ischemia. Thus, long-term modest increase in PKC activity in adult mouse hearts did not alter baseline function but did lead to improved postischemic recovery. Furthermore, our results suggest that mechanisms other than reduced acidification and preservation of high-energy phosphate levels during ischemia contribute to the improved recovery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557356      PMCID: PMC23983          DOI: 10.1073/pnas.96.23.13536

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode.

Authors:  C E Murry; V J Richard; K A Reimer; R B Jennings
Journal:  Circ Res       Date:  1990-04       Impact factor: 17.367

2.  Enhanced sensitivity to hypoxia-induced diastolic dysfunction in pressure-overload left ventricular hypertrophy in the rat: role of high-energy phosphate depletion.

Authors:  L F Wexler; B H Lorell; S Momomura; E O Weinberg; J S Ingwall; C S Apstein
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

Review 3.  Protein kinase C isoform diversity in the heart.

Authors:  S F Steinberg; M Goldberg; V O Rybin
Journal:  J Mol Cell Cardiol       Date:  1995-01       Impact factor: 5.000

4.  Mechanism of preconditioning. Ionic alterations.

Authors:  C Steenbergen; M E Perlman; R E London; E Murphy
Journal:  Circ Res       Date:  1993-01       Impact factor: 17.367

5.  Concentration-dependent effects of protein kinase C-activating and -nonactivating phorbol esters on myocardial contractility, coronary resistance, energy metabolism, prostacyclin synthesis, and ultrastructure in isolated rat hearts. Effects of amiloride.

Authors:  J E Watson; M Karmazyn
Journal:  Circ Res       Date:  1991-10       Impact factor: 17.367

6.  Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditioned segment.

Authors:  C L Wolfe; R E Sievers; F L Visseren; T J Donnelly
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

7.  Effects of brief repetitive ischemia on contractility, relaxation, and coronary flow. Exaggerated postischemic diastolic dysfunction in pressure-overload hypertrophy.

Authors:  T Mochizuki; F R Eberli; S Ngoy; C S Apstein; B H Lorell
Journal:  Circ Res       Date:  1993-09       Impact factor: 17.367

8.  In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts.

Authors:  Y Takeishi; G Chu; D M Kirkpatrick; Z Li; H Wakasaki; E G Kranias; G L King; R A Walsh
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

9.  Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts.

Authors:  Y Liu; A Tsuchida; M V Cohen; J M Downey
Journal:  J Mol Cell Cardiol       Date:  1995-03       Impact factor: 5.000

10.  Preconditioning of isolated rat heart is mediated by protein kinase C.

Authors:  M B Mitchell; X Meng; L Ao; J M Brown; A H Harken; A Banerjee
Journal:  Circ Res       Date:  1995-01       Impact factor: 17.367

View more
  8 in total

Review 1.  Protein kinase Cα as a heart failure therapeutic target.

Authors:  Qinghang Liu; Jeffery D Molkentin
Journal:  J Mol Cell Cardiol       Date:  2010-10-16       Impact factor: 5.000

2.  Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4.

Authors:  Jun Wang; Pierre Paradis; Anne Aries; Hiba Komati; Chantal Lefebvre; Hao Wang; Mona Nemer
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

3.  Protection of cardiomyocytes from ischemic/hypoxic cell death via Drbp1 and pMe2GlyDH in cardio-specific ARC transgenic mice.

Authors:  Jong-Ok Pyo; Jihoon Nah; Hyo-Jin Kim; Jae-Woong Chang; Young-Wha Song; Dong-Kwon Yang; Dong-Gyu Jo; Hyung-Ryong Kim; Han-Jung Chae; Soo-Wan Chae; Seung-Yong Hwang; Seung-Jun Kim; Hyo-Joon Kim; Chunghee Cho; Chang-Gyu Oh; Woo Jin Park; Yong-Keun Jung
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

4.  Cardiac-specific expression of the tetracycline transactivator confers increased heart function and survival following ischemia reperfusion injury.

Authors:  Laila Elsherif; Xuerong Wang; Milana Grachoff; Beata M Wolska; David L Geenen; John P O'Bryan
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

5.  PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2).

Authors:  Julian C Braz; Orlando F Bueno; Leon J De Windt; Jeffery D Molkentin
Journal:  J Cell Biol       Date:  2002-02-25       Impact factor: 10.539

Review 6.  PKC and PKN in heart disease.

Authors:  Valeria Marrocco; Julius Bogomolovas; Elisabeth Ehler; Cristobal G Dos Remedios; Jiayu Yu; Chen Gao; Stephan Lange
Journal:  J Mol Cell Cardiol       Date:  2019-02-08       Impact factor: 5.000

7.  Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.

Authors:  Qinghang Liu; Xiongwen Chen; Scott M Macdonnell; Evangelia G Kranias; John N Lorenz; Michael Leitges; Steven R Houser; Jeffery D Molkentin
Journal:  Circ Res       Date:  2009-06-25       Impact factor: 17.367

8.  Agonist activated PKCβII translocation and modulation of cardiac myocyte contractile function.

Authors:  Hyosook Hwang; Dustin Robinson; Julie B Rogers; Tamara K Stevenson; Sarah E Lang; Sakthivel Sadayappan; Sharlene M Day; Sivaraj Sivaramakrishnan; Margaret V Westfall
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.